Bookmark and Share
BioAssay: AID 2804

Summary of probe development efforts to identify activators of the Aryl Hydrocarbon Receptor (AHR)

Name: Summary of probe development efforts to identify activators of the Aryl Hydrocarbon Receptor (AHR). ..more
_
   
AID: 2804
Data Source: The Scripps Research Institute Molecular Screening Center (AHR_ACT_SUMMARY)
BioAssay Type: Summary, Candidate Probes/Leads with Supporting Evidence
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2010-05-03
Modify Date: 2012-07-23
Target
Related Experiments
Show more
AIDNameTypeComment
2796Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)Screeningdepositor-specified cross reference: Primary screen (AHR activators in singlicate)
2845Luminescence-based cell-based high throughput confirmation assay for activators of the Aryl Hydrocarbon Receptor (AHR)Screeningdepositor-specified cross reference
434939Counterscreen for activators of the Aryl Hydrocarbon Receptor (AHR): luminescence-based cell-based high throughput screening assay to identify activators of the Pregnane X Receptor (PXR)Screeningdepositor-specified cross reference
463086Luminescence-based counterscreen for activators of the Aryl Hydrocarbon Receptor (AHR): cell-based high throughput dose response screening assay for activators of the Pregnane X Receptor (PXR)Confirmatorydepositor-specified cross reference: Dose response counterscreen (PXR activators in triplicate)
463088Luminescence-based cell-based high throughput dose response assay for activators of the Aryl Hydrocarbon Receptor (AHR)Confirmatorydepositor-specified cross reference: Dose response (AHR activators in triplicate)
493060Late stage results for the probe development effort to identify activators of the Aryl Hydrocarbon Receptor (AHR): Luminescence-based cell-based dose response assay for AHR activatorsConfirmatorydepositor-specified cross reference: Dose response (AHR activators in triplicate)
493061Late stage counterscreen results for the probe development effort to identify activators of the Aryl Hydrocarbon Receptor (AHR): Luminescence-based cell-based dose response assay for activators of the Pregnane X Receptor (PXR)Confirmatorydepositor-specified cross reference: Dose response counterscreen (PXR activators in triplicate)
602169Late stage assay provider counterscreen for the probe development effort to identify activators of the Aryl Hydrocarbon Receptor (AHR): Luminescence-based Human Ovarian Carcinoma (BG1Luc4E2) Cell-based assay to identify inhibitors of Estrogen Receptor-Dependent Gene ExpressionOtherdepositor-specified cross reference: Late stage counterscreen (Estrogen Receptor-Dependent Gene Expression inhibitors)
602171Late stage assay provider counterscreen for the probe development effort to identify activators of the Aryl Hydrocarbon Receptor (AHR): Luminescence-based Human Hepatoma (HG2L7.5c1) Cell-based assay to identify activators of AhROtherdepositor-specified cross reference: Late stage counterscreen (AHR activators)
602172Late stage assay provider counterscreen for activators of Aryl hydrocarbon receptor (AHR): Radiometric electrophoretic mobility shift assay (EMSA) to identify compounds that enhance formation of AHR:DRE (dioxin response element) complexes in vitroConfirmatorydepositor-specified cross reference: Late stage counterscreen (AHR:DRE complex formation enhancers in vitro)
602173Late stage assay provider counterscreen for activators of Aryl hydrocarbon receptor (AHR): Absorbance-based cell-based assay to identify compounds that modulate proliferation of ER-negative liver cancer cells (HEPG2)Otherdepositor-specified cross reference: Late stage counterscreen (HEPG2 proliferation modulators)
602174Late stage assay provider counterscreen for activators of Aryl hydrocarbon receptor (AHR): Absorbance-based cell-based assay to identify compounds that modulate proliferation of ER-positive breast cancer cells (MCF7)Otherdepositor-specified cross reference: Late stage counterscreen (MCF7 proliferation modulators)
602226Late stage assay provider counterscreen for activators of Aryl hydrocarbon receptor (AHR): Radiometric [3H]TCDD Competitive Binding assay to identify compounds that inhibit binding of radiolabeled TCDD to AHR in cytosol isolated from guinea pig liverOtherdepositor-specified cross reference: Late stage counterscreen (Binding of radiolabeled TCDD to AHR inhibitors)
624397Late stage assay provider counterscreen for activators of Aryl hydrocarbon receptor (AHR): Absorbance-based cell-based assay to identify compounds that modulate proliferation of ER-positive breast cancer cells (MCF7), Set 2Confirmatorydepositor-specified cross reference: Late stage counterscreen (MCF7 proliferation modulators)
624398Late stage assay provider counterscreen for the probe development effort to identify activators of the Aryl Hydrocarbon Receptor (AHR): Luminescence-based Human Ovarian Carcinoma (BG1Luc4E2) Cell-based assay to identify inhibitors of Estrogen Receptor-Dependent Gene Expression, Set 2Otherdepositor-specified cross reference: Late stage counterscreen (Estrogen Receptor-Dependent Gene Expression inhibitors)
624399Late stage assay provider counterscreen for the probe development effort to identify activators of the Aryl Hydrocarbon Receptor (AHR): Luminescence-based Human Ovarian Carcinoma (BG1Luc4E2) Cell-based assay to identify activators of Estrogen Receptor-Dependent Gene ExpressionOtherdepositor-specified cross reference: Late stage counterscreen (Estrogen Receptor-Dependent Gene Expression activators)
624400Late stage assay provider counterscreen for activators of Aryl hydrocarbon receptor (AHR): Radiometric [3H]TCDD Competitive Binding assay to identify compounds that inhibit binding of radiolabeled TCDD to AHR in cytosol isolated from guinea pig liver, Set 2Otherdepositor-specified cross reference: Late stage counterscreen (Binding of radiolabeled TCDD to AHR inhibitors)
624401Late stage assay provider counterscreen for the probe development effort to identify activators of the Aryl Hydrocarbon Receptor (AHR): Luminescence-based Human Hepatoma (HG2L7.5c1) Cell-based assay to identify activators of AhR, Set 2Confirmatorydepositor-specified cross reference: Late stage counterscreen (AHR activators)
624402Late stage assay provider dose-response counterscreen for activators of Aryl hydrocarbon receptor (AhR): Radiometric electrophoretic mobility shift assay (EMSA) to identify compounds that stimulate AhR transformation and binding to its specific DNA recognition site in vitroOtherdepositor-specified cross reference: Late stage dose-response counterscreen (stimulate AhR transformation and binding to its specific DNA
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Center Affiliation: The Scripps Research Institute (TSRI)
Assay Provider: Michael Denison, University of California, Davis
Network: Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1-X01-DA026558-01
Grant Proposal PI: Michael Denison
External Assay ID: AHR_ACT_SUMMARY

Name: Summary of probe development efforts to identify activators of the Aryl Hydrocarbon Receptor (AHR).

Description:

Transcription factors are critical regulators of gene expression (1). Under conditions such as environmental stress and exposure to endogenous toxins, transcription factors can rapidly modulate the transcription of genes whose products regulate cell proliferation and metabolism. The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor of the basic helix-loop-helix protein superfamily involved in the biological response to aromatic hydrocarbons, and regulates the expression of xenobiotic-metabolizing enzymes such as cytochrome P450, aldehyde dehydrogenase, quinone reductase, and other phase I and phase II detoxification genes (2, 3). In response to various compounds, including the environmental pollutants dioxins, benzo(a)pyrene, dietary contaminants, grapefruit juice, endogenous toxins, and plant products such as carotinoids, nicotine and caffeine (2, 4-6), cytosolic AHR complexes with chaperones hsp90, p23, and XAP2, translocates to the nucleus where it dimerizes with the AHR nuclear translocator (ARNT) to influence target gene transcription (7, 8). Gain-of-function studies in mice reveal the oncogenic potential of AHR (9), while other reports show roles for AHR in diverse biologic events such as organ development (10, 11), immune function and allergy (12), and estrogen responsiveness (13). The identification of agonists of AHR will provide useful tools to elucidate the roles of this receptor in cell metabolism, transcriptional control, and tumor formation.

Summary of Probe Development Effort:

This probe development effort is focused on the identification of AHR agonists (AID 2796). All AIDs that contain results associated with this project can be found in the "Related Bioassays" section of this Summary AID.

References:

1. Ptashne, M., Regulation of transcription: from lambda to eukaryotes. Trends Biochem Sci, 2005. 30(6): p. 275-9.
2. McMillan, B.J. and Bradfield, C.A., The aryl hydrocarbon receptor sans xenobiotics: endogenous function in genetic model systems. Mol Pharmacol, 2007. 72(3): p. 487-98.
3. Puga, A., Tomlinson, C.R., and Xia, Y., Ah receptor signals cross-talk with multiple developmental pathways. Biochem Pharmacol, 2005. 69(2): p. 199-207.
4. Bock, K.W. and Kohle, C., Ah receptor: dioxin-mediated toxic responses as hints to deregulated physiologic functions. Biochem Pharmacol, 2006. 72(4): p. 393-404.
5. Denison, M.S. and Nagy, S.R., Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol, 2003. 43: p. 309-34.
6. de Waard, P.W., Peijnenburg, A.A., Baykus, H., Aarts, J.M., Hoogenboom, R.L., van Schooten, F.J., and de Kok, T.M., A human intervention study with foods containing natural Ah-receptor agonists does not significantly show AhR-mediated effects as measured in blood cells and urine. Chem Biol Interact, 2008.
7. Hankinson, O., The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol, 1995. 35: p. 307-40.
8. Petrulis, J.R. and Perdew, G.H., The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem Biol Interact, 2002. 141(1-2): p. 25-40.
9. Andersson, P., McGuire, J., Rubio, C., Gradin, K., Whitelaw, M.L., Pettersson, S., Hanberg, A., and Poellinger, L., A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc Natl Acad Sci U S A, 2002. 99(15): p. 9990-5.
10. Ramos, K.S., Transcriptional profiling and functional genomics reveal a role for AHR transcription factor in nephrogenesis. Ann N Y Acad Sci, 2006. 1076: p. 728-35.
11. Walisser, J.A., Glover, E., Pande, K., Liss, A.L., and Bradfield, C.A., Aryl hydrocarbon receptor-dependent liver development and hepatotoxicity are mediated by different cell types. Proc Natl Acad Sci U S A, 2005. 102(49): p. 17858-63.
12. Lawrence, B.P., Denison, M.S., Novak, H., Vorderstrasse, B.A., Harrer, N., Neruda, W., Reichel, C., and Woisetschlager, M., Activation of the aryl hydrocarbon receptor is essential for mediating the anti-inflammatory effects of a novel low-molecular-weight compound. Blood, 2008. 112(4): p. 1158-65.
13. Ohtake, F., Takeyama, K., Matsumoto, T., Kitagawa, H., Yamamoto, Y., Nohara, K., Tohyama, C., Krust, A., Mimura, J., Chambon, P., Yanagisawa, J., Fujii-Kuriyama, Y., and Kato, S., Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature, 2003. 423(6939): p. 545-50.

Keywords:

Summary, summary AID, AHR, bHLHe76, aryl hydrocarbon receptor, receptor, transcription factor, primary screen, primary, HTS, high throughput screen, 1536, activator, agonist, activation, luciferase, luminescence, reporter, Scripps, Scripps Florida, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN.
Categorized Comment - additional comments and annotations
From MLP Probe Report:
Probe count: 1
MLP Probe ML# for probe 1: ML363
PubChem Substance ID (SID) for probe 1: 136959031
PubChem Compound ID (CID) for probe 1: 57411924
Probe type for probe 1: Activator
IC50/EC50 (nM) for probe 1: 1.38
Target for probe 1: AhR Act (gi: 4502003)
Disease relevance for probe 1: Cancer
Anti-target for probe 1: PXR
Fold selectivity for probe 1: >10
Grant number for probe 1: DA026558-01
Additional Information
Grant Number: 1 R03 MH085678-01A1

PageFrom: